Keywords: Law suits, USA, Regulatory scrutiny, Manufacturing, GlaxoSmithKline, Bristol-Myers Squibb, FDA
Big Pharma facing law suits and increased regulatory scrutiny in the USA
Article | 23 November 2010
Last month's settlement of a case against a major pharmaceutical company, UK giant GlaxoSmithKline (LSE: GSK), regarding production violations has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
